Saturday, 10 May 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 10 May 2025
News

Newcomer knocks out second rival

 Posted 7 May 2025 AM

After beating MSD's Keytruda in a head-to-head trial last year, Akeso and partner, Summit Therapeutics, have done it again with their star performer ivonescimab "decisively beating" BeiGene's Tevimbra in lung cancer.

Chinese Biotech, Akeso, said invonescimab, a first-in-class PD-1/VEGF bispecific antibody, in combination with chemotherapy demonstrated "strongly positive results" in the Phase 3 HARMONi-6 clinical trial for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC).

To see the whole article, please login

Popular

What downturn? Pharma is back
How leaders can fix disengagement
Who's industry's 'Most Influential'?
Drug flood overwhelming HCPs
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home